Gapping up
In reaction to strong earnings/guidance:
- LPSN +20.7%, CARS +19.5%, MELI +16.4%, PERI +16.2%, ODP +13.5%, SUPN +11.6%, BYND +9.5%, HEP +9.1%, AXNX +8.9%, NEX +8.8%, WEN +7.9%, HZNP +7%, ORCC +6.7%, GM +6.7%, TMHC +6.5%, CAMP +6.3%, OSPN +6.3%, EVBG +6.1%, GSX +6.1%, SRC +6%, MEOH +6%, INMD +5.8%, ATVI +5.6%, STNG +5.4%, RSG +5.2%, ATSG +5.1%, DVN +5%, ENPH +4.8%, OXY +4.7%, RGEN +4.6%, DK +4.5%, CAKE +4%, BGS +3.9%, CVS +3.9%, SBH +3.7%, SPR +3.4%, SNN +3.2%, ONTO +3.1%, EXEL +2.8%, GEL +2.8%, DVA +2.7%, WES +2.7%, CC +2.7%, SMG +2.7%, DOOR +2.6%, AQUA +2.4%, MODN +2.3%, CGEN +2.3%, WM +2%, FLIR +2%, SHOP +1.9%, BTG +1.8%, BLDP +1.8%, DHT +1.8%, HTA +1.8%, ALXN +1.8%, IMOS +1.7%, STOR +1.6%, PSN +1.6%, HA +1.5%, GNL +1.4%, BWA +1.3%, ATGE +1.2%, NVTA +1.2%, MTCH +1.1%, TXMD +1.1%, DISCA +1.1%, WING +1.1%
Other news:
- CDTX +5% (announces new clinical and preclinical data on Cloudbreak antiviral program)
- NIO +4% (reports April deliveries increased 180.7% growth yr/yr)
- BHC +1.9% (Bausch Health and Alfasigma SpA reach resolution for XIFAXAN IP litigation)
- ABBV +1.5% (AGN and ABBV receive FTC clearance for pending acquisition)
- AGN +1.3% (AGN and ABBV receive FTC clearance for pending acquisition)
- PEP +1.2% (increases quarterly dividend)
Analyst comments:
- AEO +3.6% (upgraded to Outperform from Mkt Perform at Raymond James)
- PPG +2.1% (upgraded to Overweight from Neutral at JP Morgan)
- ADNT +1.3% (upgraded to Outperform from Sector Perform at RBC Capital Mkts)